Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain
Introduction Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the biological activity of the proinflammatory cytokines IL‐17A, IL‐17F, IL‐17A/F heterodimer, and IL‐ 25, resulting in inhibition of inflammati...
Gespeichert in:
| Veröffentlicht in: | International journal of dermatology 2023-05, Vol.62 (5), p.700-706 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 706 |
|---|---|
| container_issue | 5 |
| container_start_page | 700 |
| container_title | International journal of dermatology |
| container_volume | 62 |
| creator | Galan‐Gutierrez, Manuel Font‐Ugalde, Pilar Padilla, Laura Hernandez‐Montoya, Carlos Godoy, Daniel Armario‐Hita, Jose C. Ruiz‐Villaverde, Ricardo |
| description | Introduction
Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the biological activity of the proinflammatory cytokines IL‐17A, IL‐17F, IL‐17A/F heterodimer, and IL‐ 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti‐IL‐17 class), and survival.
Material and methods
Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate to severe plaque psoriasis in treatment with brodalumab. This cross‐sectional analysis includes information of patients between February 2019 and February 2022. A total of five tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows.
Results
Our study included 85 patients, 54 men (63.5%) and 31 women (36.5%), with moderate–severe psoriasis treated with brodalumab. In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. On week 52, mean PASI reached 1.26 and mean BSA 2.3, showing a clear stabilization and even sustained improvement regarding results on week 12. Concerning the brodalumab survival, we obtained 85.8% persistence at week 52.
Discussion
Brodalumab showed excellent results in the control of psoriasis in the mid‐term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies. |
| doi_str_mv | 10.1111/ijd.16527 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753304028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753304028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-a8f10a20d7580ed310d1970f5c664b71cb48dbd118f5caebc4b32bd1861ac5023</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMotlYXvoAE3FhwbC6TubjTeqfgQl2HTJKB1LmZzCjddevOZ-yTmDrqQjCbwzl8-RLOD8A-RifYn4mZqxMcMRJvgCGmEQvCiJJNMEQI4yBFLB2AHefmvqUEh9tgQKMwZSxhQ-DOba1E0ZUiO4WXeW6kkItj6ESuW19FpaDr7Kt5FQU0FSyNWi0_Wm1LeMTIavn-pvWzG8O6glZ7RBam8ooCNlbI1ki9vnRWrV-QRhzDh0aYahds5aJweu-7jsDT1eXj9CaY3V_fTs9mgaSMxoFIcowEQSpmCdKKYqRwGqOcySgKsxjLLExUpjBO_EjoTIYZJb5PIiwkQ4SOwFHvbWz90mnX8tI4qYtCVLruHCcxoxSFiCQePfyDzuvOVv53nCSI4JTGUeypcU9JWztndc4ba0phFxwjvk6C-yT4VxKePfg2dlmp1S_5s3oPTHrgzRR68b-J395d9MpP8H2ShQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2802193767</pqid></control><display><type>article</type><title>Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Galan‐Gutierrez, Manuel ; Font‐Ugalde, Pilar ; Padilla, Laura ; Hernandez‐Montoya, Carlos ; Godoy, Daniel ; Armario‐Hita, Jose C. ; Ruiz‐Villaverde, Ricardo</creator><creatorcontrib>Galan‐Gutierrez, Manuel ; Font‐Ugalde, Pilar ; Padilla, Laura ; Hernandez‐Montoya, Carlos ; Godoy, Daniel ; Armario‐Hita, Jose C. ; Ruiz‐Villaverde, Ricardo</creatorcontrib><description>Introduction
Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the biological activity of the proinflammatory cytokines IL‐17A, IL‐17F, IL‐17A/F heterodimer, and IL‐ 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti‐IL‐17 class), and survival.
Material and methods
Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate to severe plaque psoriasis in treatment with brodalumab. This cross‐sectional analysis includes information of patients between February 2019 and February 2022. A total of five tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows.
Results
Our study included 85 patients, 54 men (63.5%) and 31 women (36.5%), with moderate–severe psoriasis treated with brodalumab. In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. On week 52, mean PASI reached 1.26 and mean BSA 2.3, showing a clear stabilization and even sustained improvement regarding results on week 12. Concerning the brodalumab survival, we obtained 85.8% persistence at week 52.
Discussion
Brodalumab showed excellent results in the control of psoriasis in the mid‐term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.16527</identifier><identifier>PMID: 36495585</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Biological activity ; Clinical medicine ; Cross-Sectional Studies ; Dermatology ; Effectiveness ; Female ; Health services ; Humans ; Immunoglobulin G ; Inflammation ; Interleukin-17 ; Interleukins ; Male ; Monoclonal antibodies ; Patients ; Pruritus ; Psoriasis ; Psoriasis - diagnosis ; Quality of life ; Receptors, Interleukin-17 ; Retrospective Studies ; Safety ; Severity of Illness Index ; Skin diseases ; Spain ; Statistical analysis ; Survival ; Treatment Outcome</subject><ispartof>International journal of dermatology, 2023-05, Vol.62 (5), p.700-706</ispartof><rights>2022</rights><rights>2022 the International Society of Dermatology.</rights><rights>International Journal of Dermatology © 2023 International Society of Dermatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-a8f10a20d7580ed310d1970f5c664b71cb48dbd118f5caebc4b32bd1861ac5023</citedby><cites>FETCH-LOGICAL-c3537-a8f10a20d7580ed310d1970f5c664b71cb48dbd118f5caebc4b32bd1861ac5023</cites><orcidid>0000-0002-0381-6174</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijd.16527$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijd.16527$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36495585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galan‐Gutierrez, Manuel</creatorcontrib><creatorcontrib>Font‐Ugalde, Pilar</creatorcontrib><creatorcontrib>Padilla, Laura</creatorcontrib><creatorcontrib>Hernandez‐Montoya, Carlos</creatorcontrib><creatorcontrib>Godoy, Daniel</creatorcontrib><creatorcontrib>Armario‐Hita, Jose C.</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><title>Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Introduction
Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the biological activity of the proinflammatory cytokines IL‐17A, IL‐17F, IL‐17A/F heterodimer, and IL‐ 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti‐IL‐17 class), and survival.
Material and methods
Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate to severe plaque psoriasis in treatment with brodalumab. This cross‐sectional analysis includes information of patients between February 2019 and February 2022. A total of five tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows.
Results
Our study included 85 patients, 54 men (63.5%) and 31 women (36.5%), with moderate–severe psoriasis treated with brodalumab. In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. On week 52, mean PASI reached 1.26 and mean BSA 2.3, showing a clear stabilization and even sustained improvement regarding results on week 12. Concerning the brodalumab survival, we obtained 85.8% persistence at week 52.
Discussion
Brodalumab showed excellent results in the control of psoriasis in the mid‐term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies.</description><subject>Biological activity</subject><subject>Clinical medicine</subject><subject>Cross-Sectional Studies</subject><subject>Dermatology</subject><subject>Effectiveness</subject><subject>Female</subject><subject>Health services</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Inflammation</subject><subject>Interleukin-17</subject><subject>Interleukins</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pruritus</subject><subject>Psoriasis</subject><subject>Psoriasis - diagnosis</subject><subject>Quality of life</subject><subject>Receptors, Interleukin-17</subject><subject>Retrospective Studies</subject><subject>Safety</subject><subject>Severity of Illness Index</subject><subject>Skin diseases</subject><subject>Spain</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Treatment Outcome</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctKAzEUhoMotlYXvoAE3FhwbC6TubjTeqfgQl2HTJKB1LmZzCjddevOZ-yTmDrqQjCbwzl8-RLOD8A-RifYn4mZqxMcMRJvgCGmEQvCiJJNMEQI4yBFLB2AHefmvqUEh9tgQKMwZSxhQ-DOba1E0ZUiO4WXeW6kkItj6ESuW19FpaDr7Kt5FQU0FSyNWi0_Wm1LeMTIavn-pvWzG8O6glZ7RBam8ooCNlbI1ki9vnRWrV-QRhzDh0aYahds5aJweu-7jsDT1eXj9CaY3V_fTs9mgaSMxoFIcowEQSpmCdKKYqRwGqOcySgKsxjLLExUpjBO_EjoTIYZJb5PIiwkQ4SOwFHvbWz90mnX8tI4qYtCVLruHCcxoxSFiCQePfyDzuvOVv53nCSI4JTGUeypcU9JWztndc4ba0phFxwjvk6C-yT4VxKePfg2dlmp1S_5s3oPTHrgzRR68b-J395d9MpP8H2ShQ</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Galan‐Gutierrez, Manuel</creator><creator>Font‐Ugalde, Pilar</creator><creator>Padilla, Laura</creator><creator>Hernandez‐Montoya, Carlos</creator><creator>Godoy, Daniel</creator><creator>Armario‐Hita, Jose C.</creator><creator>Ruiz‐Villaverde, Ricardo</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid></search><sort><creationdate>202305</creationdate><title>Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain</title><author>Galan‐Gutierrez, Manuel ; Font‐Ugalde, Pilar ; Padilla, Laura ; Hernandez‐Montoya, Carlos ; Godoy, Daniel ; Armario‐Hita, Jose C. ; Ruiz‐Villaverde, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-a8f10a20d7580ed310d1970f5c664b71cb48dbd118f5caebc4b32bd1861ac5023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biological activity</topic><topic>Clinical medicine</topic><topic>Cross-Sectional Studies</topic><topic>Dermatology</topic><topic>Effectiveness</topic><topic>Female</topic><topic>Health services</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Inflammation</topic><topic>Interleukin-17</topic><topic>Interleukins</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pruritus</topic><topic>Psoriasis</topic><topic>Psoriasis - diagnosis</topic><topic>Quality of life</topic><topic>Receptors, Interleukin-17</topic><topic>Retrospective Studies</topic><topic>Safety</topic><topic>Severity of Illness Index</topic><topic>Skin diseases</topic><topic>Spain</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galan‐Gutierrez, Manuel</creatorcontrib><creatorcontrib>Font‐Ugalde, Pilar</creatorcontrib><creatorcontrib>Padilla, Laura</creatorcontrib><creatorcontrib>Hernandez‐Montoya, Carlos</creatorcontrib><creatorcontrib>Godoy, Daniel</creatorcontrib><creatorcontrib>Armario‐Hita, Jose C.</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galan‐Gutierrez, Manuel</au><au>Font‐Ugalde, Pilar</au><au>Padilla, Laura</au><au>Hernandez‐Montoya, Carlos</au><au>Godoy, Daniel</au><au>Armario‐Hita, Jose C.</au><au>Ruiz‐Villaverde, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>62</volume><issue>5</issue><spage>700</spage><epage>706</epage><pages>700-706</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><abstract>Introduction
Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the biological activity of the proinflammatory cytokines IL‐17A, IL‐17F, IL‐17A/F heterodimer, and IL‐ 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti‐IL‐17 class), and survival.
Material and methods
Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate to severe plaque psoriasis in treatment with brodalumab. This cross‐sectional analysis includes information of patients between February 2019 and February 2022. A total of five tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows.
Results
Our study included 85 patients, 54 men (63.5%) and 31 women (36.5%), with moderate–severe psoriasis treated with brodalumab. In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. On week 52, mean PASI reached 1.26 and mean BSA 2.3, showing a clear stabilization and even sustained improvement regarding results on week 12. Concerning the brodalumab survival, we obtained 85.8% persistence at week 52.
Discussion
Brodalumab showed excellent results in the control of psoriasis in the mid‐term with an elevated number of patients maintaining treatment after 52 weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36495585</pmid><doi>10.1111/ijd.16527</doi><tpages>706</tpages><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-9059 |
| ispartof | International journal of dermatology, 2023-05, Vol.62 (5), p.700-706 |
| issn | 0011-9059 1365-4632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753304028 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological activity Clinical medicine Cross-Sectional Studies Dermatology Effectiveness Female Health services Humans Immunoglobulin G Inflammation Interleukin-17 Interleukins Male Monoclonal antibodies Patients Pruritus Psoriasis Psoriasis - diagnosis Quality of life Receptors, Interleukin-17 Retrospective Studies Safety Severity of Illness Index Skin diseases Spain Statistical analysis Survival Treatment Outcome |
| title | Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brodalumab:%20Efficacy,%20safety,%20and%20survival%20in%20mid%E2%80%90term%20(52%E2%80%89weeks)%20on%20real%20clinical%20practice%20in%20Andalucia,%20Spain&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Galan%E2%80%90Gutierrez,%20Manuel&rft.date=2023-05&rft.volume=62&rft.issue=5&rft.spage=700&rft.epage=706&rft.pages=700-706&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.16527&rft_dat=%3Cproquest_cross%3E2753304028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2802193767&rft_id=info:pmid/36495585&rfr_iscdi=true |